Lodenosine (FddA), a nucleoside reverse transcriptase inhibitor, has shown promising antiretroviral activity in nitro and in a Phase I study in HIV-1 infected patients, most of whom were heavily pre-treated. The purpose of this study is to investigate the most appropriate dose of lodenosine to be used as part of triple combination therapy for HIV-l infected adults starting therapy for the first time. Three dose levels of FddA will be tested in combination with stavidine and indinavir.
Showing the most recent 10 out of 423 publications